Skip to main navigation Skip to search Skip to main content

Esophageal and esophagogastric junction cancers, Version 1.2015

  • Jaffer A. Ajani
  • , Thomas A. D'Amico
  • , Khaldoun Almhanna
  • , David J. Bentrem
  • , Stephen Besh
  • , Joseph Chao
  • , Prajnan Das
  • , Crystal Denlinger
  • , Paul Fanta
  • , Charles S. Fuchs
  • , Hans Gerdes
  • , Robert E. Glasgow
  • , James A. Hayman
  • , Steven Hochwald
  • , Wayne L. Hofstetter
  • , David H. Ilson
  • , Dawn Jaroszewski
  • , Kory Jasperson
  • , Rajesh N. Keswani
  • , Lawrence R. Kleinberg
  • W. Michael Korn, Stephen Leong, A. Craig Lockhart, Mary F. Mulcahy, Mark B. Orringer, James A. Posey, George A. Poultsides, Aaron R. Sasson, Walter J. Scott, Vivian E. Strong, Thomas K. Varghese, Mary Kay Washington, Christopher G. Willett, Cameron D. Wright, Debra Zelman, Nicole McMillian, Hema Sundar
  • University of Texas MD Anderson Cancer Center
  • Duke University
  • Moffitt Cancer Center
  • Northwestern University
  • University of Tennessee Health Science Center
  • City of Hope National Med Center
  • Fox Chase Cancer Center
  • University of California at San Diego
  • Dana-Farber/Brigham and Women's Cancer Center
  • Memorial Sloan-Kettering Cancer Center
  • University of Utah
  • University of Michigan, Ann Arbor
  • Roswell Park Cancer Institute
  • Mayo Clinic Rochester, MN
  • Johns Hopkins University
  • University of California at San Francisco
  • University of Colorado Anschutz Medical Campus
  • Washington University St. Louis
  • University of Alabama at Birmingham
  • Stanford University
  • Seattle Cancer Care Alliance
  • Vanderbilt University
  • Massachusetts General Hospital Cancer Center
  • Debbie's Dream Foundation: Curing Stomach Cancer

Research output: Contribution to journalReview articlepeer-review

337 Scopus citations

Abstract

Esophageal cancer is the sixth most common cause of cancer deaths worldwide. Adenocarcinoma is more common in North America and Western European countries, originating mostly in the lower third of the esophagus, which often involves the esophagogastric junction (EGJ). Recent randomized trials have shown that the addition of preoperative chemoradiation or perioperative chemotherapy to surgery significantly improves survival in patients with resectable cancer. Targeted therapies with trastuzumab and ramucirumab have produced encouraging results in the treatment of advanced or metastatic EGJ adenocarcinomas. Multidisciplinary team management is essential for patients with esophageal and EGJ cancers. This portion of the NCCN Guidelines for Esophageal and EGJ Cancers discusses management of locally advanced adenocarcinoma of the esophagus and EGJ.

Original languageEnglish
Pages (from-to)194-227
Number of pages34
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume13
Issue number2
DOIs
StatePublished - Feb 1 2015

Fingerprint

Dive into the research topics of 'Esophageal and esophagogastric junction cancers, Version 1.2015'. Together they form a unique fingerprint.

Cite this